Town & Country Bank & Trust CO dba First Bankers Trust CO Sells 8,058 Shares of Pfizer Inc. (NYSE:PFE)

Town & Country Bank & Trust CO dba First Bankers Trust CO lessened its position in Pfizer Inc. (NYSE:PFE) by 19.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 32,453 shares of the biopharmaceutical company’s stock after selling 8,058 shares during the quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Pfizer were worth $901,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Teza Capital Management LLC bought a new position in Pfizer during the third quarter worth $347,000. Caxton Associates LP raised its position in shares of Pfizer by 7.2% during the third quarter. Caxton Associates LP now owns 45,018 shares of the biopharmaceutical company’s stock valued at $1,493,000 after buying an additional 3,043 shares during the last quarter. United Services Automobile Association grew its position in Pfizer by 1.5% during the third quarter. United Services Automobile Association now owns 1,510,368 shares of the biopharmaceutical company’s stock worth $50,099,000 after buying an additional 22,731 shares in the last quarter. Bluefin Capital Management LLC bought a new position in Pfizer during the third quarter valued at about $358,000. Finally, White Knight Strategic Wealth Advisors LLC lifted its position in shares of Pfizer by 3.0% in the 3rd quarter. White Knight Strategic Wealth Advisors LLC now owns 20,528 shares of the biopharmaceutical company’s stock worth $681,000 after acquiring an additional 604 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently commented on PFE shares. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Morgan Stanley raised their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Wednesday. Nine analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $35.54.

Pfizer Price Performance

Pfizer stock traded up $0.18 on Friday, reaching $27.98. The company’s stock had a trading volume of 33,189,215 shares, compared to its average volume of 34,031,364. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $37.80. The company has a market cap of $158.55 billion, a price-to-earnings ratio of -466.26, a PEG ratio of 1.10 and a beta of 0.70. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The business’s fifty day moving average price is $27.90 and its 200 day moving average price is $27.68.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same quarter in the prior year, the firm earned $1.23 EPS. The company’s revenue was down 19.5% on a year-over-year basis. Equities analysts expect that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.00%. The ex-dividend date is Thursday, July 25th. Pfizer’s dividend payout ratio is -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.